CareDx, Inc.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
CDNA$80.77-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net income (loss) | $132,737 | $(17,246) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Stock-based compensation | 30,112 | 26,773 |
| Depreciation and amortization | 13,914 | 11,136 |
| Impairment of intangible asset and associated construction in progress | — | 2,258 |
| Amortization of right-of-use assets | 4,517 | 4,020 |
| Loss on disposal of asset | 210 | — |
| Gain on sale of lab products business | (112,966) | — |
| Revaluation of contingent consideration to estimated fair value | — | 547 |
| Non-cash income tax benefit in connection with business acquisition (Note 6) | (9,839) | — |
| Amortization of premium and accretion of discount on marketable securities, net | 1,414 | 1,493 |
| Other | 492 | 48 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (9,016) | 17,215 |
| Inventory | 1,085 | (6,993) |
| Prepaid and other assets | (6,870) | (8,359) |
| Operating leases liabilities, net | (4,967) | (4,455) |
| Accounts payable | 2,185 | 3,186 |
| Accrued compensation | 2,726 | (15,438) |
| Accrued and other liabilities | (420) | 5,542 |
| Deferred revenue | 2,341 | 942 |
| Net cash provided by operating activities | 47,655 | 20,669 |
| Investing activities: | ||
| Acquisition of Naveris, Inc., net of cash acquired | (145,769) | — |
| Acquisition of intangible asset | — | (675) |
| Purchases of marketable securities | (39,850) | (84,351) |
| Maturities of marketable securities | 59,744 | 126,039 |
| Sales of marketable securities | 114,636 | — |
| Purchase of long term investment | (2,500) | — |
| Proceeds from sale of lab products business, net | 164,792 | — |
| Additions of property and equipment | (7,292) | (3,942) |
| Net cash provided by investing activities | 143,761 | 37,071 |
| Financing activities: | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 2,497 | 2,272 |
| Taxes paid related to net share settlement of restricted stock units | (13,097) | (10,451) |
| Proceeds from exercise of stock options | 18,822 | 4,310 |
| Payment of contingent consideration | (1,500) | (1,500) |
| Repurchase and retirement of common stock | (12,232) | (75,563) |
| Net cash used in financing activities | (5,510) | (80,932) |
| Effect of exchange rate changes on cash and cash equivalents | 4 | (96) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 185,910 | (23,288) |
| Cash, cash equivalents and restricted cash at beginning of period | 65,980 | 115,274 |
| Cash, cash equivalents and restricted cash at end of period | $251,890 | $91,986 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.